GRIFOLS S A/S (NASDAQ:GRFS) Lifted to Hold at ValuEngine

ValuEngine upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a sell rating to a hold rating in a research note released on Saturday morning, ValuEngine reports.

GRFS has been the subject of several other research reports. Zacks Investment Research raised shares of GRIFOLS S A/S from a strong sell rating to a hold rating in a report on Wednesday, June 24th. Kepler Capital Markets restated a hold rating on shares of GRIFOLS S A/S in a research note on Friday, March 27th. HSBC upgraded shares of GRIFOLS S A/S from a reduce rating to a hold rating in a research note on Tuesday, June 9th. Barclays restated an overweight rating on shares of GRIFOLS S A/S in a research note on Monday, June 1st. Finally, JPMorgan Chase & Co. cut shares of GRIFOLS S A/S from an overweight rating to a neutral rating in a research note on Tuesday, April 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $24.00.

Shares of GRFS opened at $18.64 on Friday. GRIFOLS S A/S has a 1 year low of $13.40 and a 1 year high of $25.73. The company has a market cap of $12.84 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 0.99 and a beta of 0.83. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.90 and a current ratio of 2.75. The firm has a fifty day moving average of $19.60 and a 200-day moving average of $21.40.

GRIFOLS S A/S (NASDAQ:GRFS) last announced its quarterly earnings results on Tuesday, April 21st. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.01. GRIFOLS S A/S had a net margin of 13.31% and a return on equity of 11.92%. The company had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.40 billion. Analysts predict that GRIFOLS S A/S will post 1.36 EPS for the current year.

Institutional investors have recently modified their holdings of the business. FMR LLC raised its position in GRIFOLS S A/S by 185.7% in the fourth quarter. FMR LLC now owns 25,886 shares of the biotechnology company’s stock worth $603,000 after acquiring an additional 16,825 shares in the last quarter. Two Sigma Advisers LP raised its position in GRIFOLS S A/S by 17.0% in the first quarter. Two Sigma Advisers LP now owns 388,700 shares of the biotechnology company’s stock worth $7,828,000 after acquiring an additional 56,600 shares in the last quarter. JPMorgan Chase & Co. raised its position in GRIFOLS S A/S by 33.2% in the first quarter. JPMorgan Chase & Co. now owns 660,551 shares of the biotechnology company’s stock worth $13,303,000 after acquiring an additional 164,526 shares in the last quarter. Norges Bank bought a new stake in GRIFOLS S A/S in the fourth quarter worth about $70,212,000. Finally, BNP Paribas Arbitrage SA raised its position in GRIFOLS S A/S by 248.7% in the first quarter. BNP Paribas Arbitrage SA now owns 99,154 shares of the biotechnology company’s stock worth $1,997,000 after acquiring an additional 70,716 shares in the last quarter. Hedge funds and other institutional investors own 17.88% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

See Also: Diluted Earnings Per Share

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.